Ss Homoeo Doctor Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 16 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 36.60%
- Profit Growth -17.76%
- Ebitda -15.13%
- Net Worth 17.04%
- Total Assets 69.02%
About Ss Homoeo Doctor Pharmaceuticals
Ss Homoeo Doctor Pharmaceuticals Private Limited (SHDPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 March 2008 and has a history of 16 years and 11 months. Its registered office is in Faridabad, Haryana, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anju Singh, Satrughan Singh, and Ujjwal Singh serve as directors at the Company.
Company Details
- Location
Faridabad, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232HR2008PTC037717
- Company No.
037717
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Ss Homoeo Doctor Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anju Singh  | Director | 17-Mar-2008 | Current |
| Satrughan Singh | Director | 16-Jun-2010 | Current |
| Ujjwal Singh | Director | 23-Aug-2022 | Current |
Financial Performance of Ss Homoeo Doctor Pharmaceuticals.
Ss Homoeo Doctor Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 36.6% increase. The company also saw a substantial fall in profitability, with a 17.76% decrease in profit. The company's net worth Soared by an impressive increase of 17.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ss Homoeo Doctor Pharmaceuticals?
In 2017, Ss Homoeo Doctor Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ss Homoeo Doctor Pharmaceuticals?
Ss Homoeo Doctor Pharmaceuticals has a workforce of 11 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ss Homoeo Doctor Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ss Homoeo Doctor Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
